These are top 10 stocks traded on the Robinhood UK platform in July
In a stark reflection of investor sentiment, Passage Bio Inc (PASG) stock has tumbled to a 52-week low, touching a price level of just $0.35, marking a dramatic 74% decline from its 52-week high of $1.64. According to InvestingPro analysis, the company currently appears undervalued based on its Fair Value metrics. This latest dip underscores a prolonged bearish trend for the biotechnology firm, which has seen its market value erode by a staggering 74.12% over the past year. The company, which specializes in genetic medicines for rare, monogenic central nervous system disorders, has faced a series of challenges that have evidently shaken the confidence of shareholders, leading to a significant sell-off and the current low valuation. Despite these challenges, InvestingPro data shows the company maintains a healthy current ratio of 4.07 and holds more cash than debt on its balance sheet. The 52-week low marks a critical juncture for Passage Bio as it navigates through a tough phase in its corporate trajectory. Get access to 12 additional InvestingPro Tips and comprehensive financial analysis at InvestingPro.
In other recent news, Passage Bio Inc. reported its fourth quarter and full-year 2024 financial results, revealing a reduction in cash, cash equivalents, and marketable securities to $76.8 million from $84.8 million at the end of the previous quarter. Chardan Capital Markets responded by lowering its price target for Passage Bio shares to $6.00 from $7.00, while maintaining a Buy rating. The company’s strategic changes, including a workforce reduction of approximately 55% and outsourcing analytical testing, are projected to extend its financial runway into the first quarter of 2027. Passage Bio also announced that updated data from its upliFT-D trial is expected in the second half of 2025. Additionally, Passage Bio has transitioned its stock listing from The Nasdaq Global Select Market to The Nasdaq Capital Market due to non-compliance with the minimum bid price requirement. This move grants the company an additional 180 days to meet the requirement by July 28, 2025. Passage Bio’s management is actively exploring options, including a potential reverse stock split, to address the compliance issue. The transition aims to maintain the company’s Nasdaq listing while ensuring uninterrupted trading of its shares.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.